[go: up one dir, main page]

PE20220488A1 - Variantes del cnp y sus conjugados - Google Patents

Variantes del cnp y sus conjugados

Info

Publication number
PE20220488A1
PE20220488A1 PE2022000426A PE2022000426A PE20220488A1 PE 20220488 A1 PE20220488 A1 PE 20220488A1 PE 2022000426 A PE2022000426 A PE 2022000426A PE 2022000426 A PE2022000426 A PE 2022000426A PE 20220488 A1 PE20220488 A1 PE 20220488A1
Authority
PE
Peru
Prior art keywords
seq
variant
group
cnp
conjugates
Prior art date
Application number
PE2022000426A
Other languages
English (en)
Inventor
Daniel J Wendt
Geoffrey Berguig
Karol Estrada
Jonathan Lebowitz
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Publication of PE20220488A1 publication Critical patent/PE20220488A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Referida a una variante del peptido natriuretico de tipo C seleccionado del grupo que consiste en: PGQEHPQARRYRGAQRRGLSRGCFGLKLDRIGSMSGLGC (SEQ ID NO:5); PGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (SEQ ID NO:1); PGQEHPNARRYRGANRRGLSRGCFGLKLDRIGSMSGLGC (SEQ ID NO:6); y PGQEHPQARKYKGAQKKGLSKGCFGLKLDRIGSMSGLGC (SEQ ID NO:7). El peptido comprende, ademas, un grupo acetilo en el extremo N-terminal y un grupo OH o un NH2 en el extremo C-terminal. Tambien esta referida a una composicion farmaceutica que comprende dicha variante. La variante es util en el tratamiento de trastornos relacionados con los huesos tales como displasias esqueleticas.
PE2022000426A 2019-09-16 2020-09-16 Variantes del cnp y sus conjugados PE20220488A1 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201962901093P 2019-09-16 2019-09-16
US201962935050P 2019-11-13 2019-11-13
US202062963350P 2020-01-20 2020-01-20
US202062964852P 2020-01-23 2020-01-23
US202063038667P 2020-06-12 2020-06-12
PCT/US2020/051100 WO2021055497A1 (en) 2019-09-16 2020-09-16 Cnp variants and conjugates thereof

Publications (1)

Publication Number Publication Date
PE20220488A1 true PE20220488A1 (es) 2022-04-04

Family

ID=72709850

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022000426A PE20220488A1 (es) 2019-09-16 2020-09-16 Variantes del cnp y sus conjugados

Country Status (15)

Country Link
US (1) US20230192799A1 (es)
EP (1) EP4031183A1 (es)
JP (2) JP7758663B2 (es)
KR (1) KR20220063220A (es)
CN (1) CN114616242A (es)
AU (1) AU2020349493A1 (es)
BR (1) BR112022004697A2 (es)
CA (1) CA3153730A1 (es)
CL (1) CL2023001727A1 (es)
CO (1) CO2022004335A2 (es)
IL (1) IL291179A (es)
MX (1) MX2022003184A (es)
PE (1) PE20220488A1 (es)
TW (1) TW202124422A (es)
WO (1) WO2021055497A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024000526A (es) 2021-07-09 2024-02-02 Biomarin Pharm Inc Variantes del peptido natriuretico tipo c para tratar la displasia esqueletica en ni?os.
PE20242041A1 (es) 2021-12-07 2024-10-10 Biomarin Pharm Inc Terapia con peptido natriuretico tipo c de trastornos relacionados con los huesos
AU2022413318A1 (en) 2021-12-13 2024-05-16 Ascendis Pharma Growth Disorders A/S Effective doses of cnp conjugates
WO2023117855A1 (en) * 2021-12-20 2023-06-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of analog of c-type natriuretic peptide for the treatment of fgfr-related bone repair and bone formation impairment
IL316466A (en) 2022-05-23 2024-12-01 Ascendis Pharma Growth Disorders As Liquid pharmaceutical formulations of cnp compounds
WO2024094747A1 (en) * 2022-11-02 2024-05-10 Novo Nordisk A/S Cnp compounds
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
JP2026500069A (ja) * 2023-03-09 2026-01-06 メルク・シャープ・アンド・ドーム・エルエルシー ＡｃｔＲＩＩＡタンパク質変異体を含む製剤
CN121219011A (zh) 2023-03-20 2025-12-26 阿森迪斯药物生长障碍股份有限公司 治疗患有软骨发育不全患者胸腰椎畸形的方法
TW202513806A (zh) 2023-06-07 2025-04-01 美商拜奧馬林製藥公司 高通量篩選與身材矮小相關之基因變異體
WO2025076498A1 (en) * 2023-10-06 2025-04-10 Biomarin Pharmaceutical Inc. Treatment of osteogenesis imperfecta with c-type natriuretic peptide and analogs thereof
WO2025101863A1 (en) * 2023-11-08 2025-05-15 Biomarin Pharmaceutical Inc. Cnp variants, conjugates and formulations thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991016342A1 (fr) 1990-04-20 1991-10-31 Hisayuki Matsuo Nouveau peptide a activite physiologique d'origine porcine
JP3026354B2 (ja) 1990-09-27 2000-03-27 壽之 松尾 ヒトｃｎｐ遺伝子及び前駆体蛋白
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
TWI471137B (zh) 2009-05-20 2015-02-01 Biomarin Pharm Inc Ｃ型利鈉胜肽變異體
JP5871905B2 (ja) 2011-03-30 2016-03-01 ベータ ファーマシューティカルズ カンパニー リミテッド グルカゴン様ペプチド−１類似体およびその使用
CN114796460A (zh) * 2015-07-30 2022-07-29 生物马林药物股份有限公司 C型利尿钠肽变体在治疗骨骼发育不良中的用途
AU2017205688C1 (en) * 2016-01-08 2022-03-10 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with carrier attachment at the ring moiety

Also Published As

Publication number Publication date
CL2023001727A1 (es) 2024-01-12
MX2022003184A (es) 2022-06-23
CO2022004335A2 (es) 2022-08-30
BR112022004697A2 (pt) 2022-06-14
TW202124422A (zh) 2021-07-01
JP2025162558A (ja) 2025-10-27
EP4031183A1 (en) 2022-07-27
JP2022547723A (ja) 2022-11-15
CA3153730A1 (en) 2021-03-25
JP7758663B2 (ja) 2025-10-22
IL291179A (en) 2022-05-01
US20230192799A1 (en) 2023-06-22
AU2020349493A1 (en) 2022-04-07
CN114616242A (zh) 2022-06-10
WO2021055497A1 (en) 2021-03-25
KR20220063220A (ko) 2022-05-17

Similar Documents

Publication Publication Date Title
PE20220488A1 (es) Variantes del cnp y sus conjugados
MX2021011278A (es) Composicion farmaceutica para inyeccion subcutanea que comprende una variante de hialuronidasa humana ph20 y un farmaco.
PE20240015A1 (es) Proteinas de fusion gdf15 y usos de estas
PE20120792A1 (es) Variantes de peptidos natriureticos de tipo c
MX2023002973A (es) Uso de variantes de peptido natriuretico de tipo c para tratar displasia esqueletica.
PE20200926A1 (es) Peptidos analogos de incretina
CL2019002132A1 (es) Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinético y sus usos.
AR072009A1 (es) Mutantes del factor de crecimiento de los fibroblastos fgf21 y usos de los mismos
CO6190536A2 (es) Vacunas peptidicas para canceres que expresan antigenos asociados con tumores
HN2009001593A (es) Coagnistas de receptor de glucagon/glp-1
PE20211466A1 (es) Analogos de proteina tirosina-tirosina y metodos de uso de esta
MX2015002994A (es) Peptidos de inhibidores obtenidos del receptor desencadenante expresado en celulas mieloides de tipo 1 (trem-1) y transcrito similar a trem 1 (tlt-1) y usos de los mismos.
RU2021134101A (ru) Модифицированная j-цепь
ECSP056236A (es) Agonistas del receptor de la melanocortina 4 (mc4) y sus usos
MX339277B (es) Agente inductor de inmunidad.
PE20231639A1 (es) Compuestos co-agonistas del glucagon y peptido-1 similar al glugacon (glp-1)
PE20200514A1 (es) Compuestos de mic-1 y usos de estos
PE20081140A1 (es) Agentes terapeuticos a base de peptidos derivados de toxinas
MX2017016105A (es) Polinucleotidos y polipeptidos de adenovirus.
AR069409A1 (es) Variantes de peptidos natriureticos de tipo c
PE20091214A1 (es) Sintesis de peptidos insulinotropicos utilizando una combinacion de tecnicas en fase solida y en solucion
AR096162A1 (es) Péptidos terapéuticos
PE20181376A1 (es) Analogos del egf(a) con sustituyentes de acidos grasos
MX2024005173A (es) Composicion farmaceutica que comprende hialuronidasa humana ph20 y farmaco.
FI3737399T3 (fi) ATF5-peptidivariantit ja niiden käytöt